CH674203A5 - - Google Patents
Download PDFInfo
- Publication number
- CH674203A5 CH674203A5 CH2617/85A CH261785A CH674203A5 CH 674203 A5 CH674203 A5 CH 674203A5 CH 2617/85 A CH2617/85 A CH 2617/85A CH 261785 A CH261785 A CH 261785A CH 674203 A5 CH674203 A5 CH 674203A5
- Authority
- CH
- Switzerland
- Prior art keywords
- phenyl
- compound
- compounds
- formula
- group
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 179
- -1 tri-substituted phenyl Chemical group 0.000 claims description 94
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims description 35
- 241001465754 Metazoa Species 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 20
- 101800001982 Cholecystokinin Proteins 0.000 claims description 18
- 102100025841 Cholecystokinin Human genes 0.000 claims description 18
- 229940107137 cholecystokinin Drugs 0.000 claims description 18
- 230000000202 analgesic effect Effects 0.000 claims description 16
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 15
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 230000002921 anti-spasmodic effect Effects 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 7
- 150000008064 anhydrides Chemical class 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 230000000975 bioactive effect Effects 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N glutamic acid Chemical compound OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 230000036407 pain Effects 0.000 claims description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- 208000022531 anorexia Diseases 0.000 claims description 4
- 229960005261 aspartic acid Drugs 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 206010061428 decreased appetite Diseases 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 230000001989 choleretic effect Effects 0.000 claims description 3
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 2
- 150000001263 acyl chlorides Chemical class 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 229960002989 glutamic acid Drugs 0.000 claims description 2
- 239000012442 inert solvent Substances 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000002948 appetite stimulant Substances 0.000 claims 1
- 229940029995 appetite stimulants Drugs 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 104
- 229910001868 water Inorganic materials 0.000 description 49
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- 230000000694 effects Effects 0.000 description 42
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 229960005181 morphine Drugs 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 19
- 108010087230 Sincalide Proteins 0.000 description 17
- 238000010609 cell counting kit-8 assay Methods 0.000 description 17
- 241000700159 Rattus Species 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 210000000232 gallbladder Anatomy 0.000 description 10
- 239000000047 product Substances 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 241000700199 Cavia porcellus Species 0.000 description 6
- 239000000730 antalgic agent Substances 0.000 description 6
- 230000008602 contraction Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 5
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 229940035676 analgesics Drugs 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 229940005483 opioid analgesics Drugs 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 4
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 230000001595 contractor effect Effects 0.000 description 4
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 4
- 229960004193 dextropropoxyphene Drugs 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 230000003533 narcotic effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 3
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- XCKKIKBIPZJUET-VYKNHSEDSA-N morphine hydrochloride Chemical compound Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XCKKIKBIPZJUET-VYKNHSEDSA-N 0.000 description 3
- 229940124636 opioid drug Drugs 0.000 description 3
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- UCFHLGYZODDCIJ-HACHORDNSA-N (2r)-2-benzamido-3,4-dichloropentanedioic acid Chemical compound OC(=O)C(Cl)C(Cl)[C@@H](C(O)=O)NC(=O)C1=CC=CC=C1 UCFHLGYZODDCIJ-HACHORDNSA-N 0.000 description 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- 125000006304 2-iodophenyl group Chemical group [H]C1=C([H])C(I)=C(*)C([H])=C1[H] 0.000 description 2
- 125000004362 3,4,5-trichlorophenyl group Chemical group [H]C1=C(Cl)C(Cl)=C(Cl)C([H])=C1* 0.000 description 2
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 2
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 208000003770 biliary dyskinesia Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- FXCTZFMSAHZQTR-KAMYIIQDSA-N cpccoet Chemical compound O\N=C/1C2=CC=CC=C2OC2(C(=O)OCC)C\1C2 FXCTZFMSAHZQTR-KAMYIIQDSA-N 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960001797 methadone Drugs 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 229960000649 oxyphenbutazone Drugs 0.000 description 2
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- PNCQTRSFSYUTDV-VIFPVBQESA-N (2s)-2-[(3,4-dichlorobenzoyl)amino]pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)C1=CC=C(Cl)C(Cl)=C1 PNCQTRSFSYUTDV-VIFPVBQESA-N 0.000 description 1
- RJEUERNNQHNSKG-CCKFTAQKSA-N (2s)-2-amino-n-[(2r)-1-[[2-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)propanamide Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=C(O)C=C1 RJEUERNNQHNSKG-CCKFTAQKSA-N 0.000 description 1
- GWKOSRIHVSBBIA-REOHCLBHSA-N (3s)-3-aminooxolane-2,5-dione Chemical class N[C@H]1CC(=O)OC1=O GWKOSRIHVSBBIA-REOHCLBHSA-N 0.000 description 1
- OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 1
- LHUMPWOBZPBWRA-VIFPVBQESA-N 3,4-dichloro-n-[(3s)-2,6-dioxooxan-3-yl]benzamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(=O)N[C@@H]1C(=O)OC(=O)CC1 LHUMPWOBZPBWRA-VIFPVBQESA-N 0.000 description 1
- WKUFGZSXYMXLPA-UHFFFAOYSA-N 4-(3,4-dimethylphenyl)morpholine Chemical compound C1=C(C)C(C)=CC=C1N1CCOCC1 WKUFGZSXYMXLPA-UHFFFAOYSA-N 0.000 description 1
- BYBJDDZACMHGTC-UHFFFAOYSA-N 5-(dibutylamino)-4-[(3,4-dichlorobenzoyl)amino]-5-oxopentanoic acid Chemical compound CCCCN(CCCC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=C(Cl)C(Cl)=C1 BYBJDDZACMHGTC-UHFFFAOYSA-N 0.000 description 1
- 101150034533 ATIC gene Proteins 0.000 description 1
- 101150047265 COR2 gene Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 101100467189 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) QCR2 gene Proteins 0.000 description 1
- 101150103331 Simc1 gene Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- GGISZLOBBISXOZ-UHFFFAOYSA-N acetic acid;chloroform Chemical compound CC(O)=O.ClC(Cl)Cl GGISZLOBBISXOZ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 230000010234 biliary secretion Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001953 common bile duct Anatomy 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- YDGWVHHYXBMDAD-UHFFFAOYSA-N ethyl formate;propan-2-one Chemical compound CC(C)=O.CCOC=O YDGWVHHYXBMDAD-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001706 oxygenating effect Effects 0.000 description 1
- 229940096717 pamine Drugs 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- CXYRUNPLKGGUJF-RAFJPFSSSA-M scopolamine methobromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 CXYRUNPLKGGUJF-RAFJPFSSSA-M 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000003384 transverse colon Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 235000012712 vegetable carbon Nutrition 0.000 description 1
- 239000004108 vegetable carbon Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/66—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT67644/84A IT1178982B (it) | 1984-06-25 | 1984-06-25 | Derivati del acido gludamico aventi attivita antagonista su polipep tidi bioattivi e procedimento per la loro preparazione |
| IT68070/84A IT1196751B (it) | 1984-10-26 | 1984-10-26 | Alogeno e ciano derivati dell'acido glutammico ed aspartico ad attivita antagonista su polipeptidi bioattivi e procedimento per la loro preparazione |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH674203A5 true CH674203A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1990-05-15 |
Family
ID=26329809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH2617/85A CH674203A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1984-06-25 | 1985-06-20 |
Country Status (15)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1215169B (it) * | 1985-12-17 | 1990-01-31 | Rotta Research Lab | Derivati alchil ossigenati degli acidi glutammico ed aspartico ad attivita antagonista su polipeptidi bioattivi e procedimento per la loro preparazione |
| US5089638A (en) * | 1986-06-16 | 1992-02-18 | Merck & Co., Inc. | Amino acid analogs as CCK-antagonists |
| US4880938A (en) * | 1986-06-16 | 1989-11-14 | Merck & Co., Inc. | Amino acid analogs |
| IT1196849B (it) * | 1986-12-16 | 1988-11-25 | Rotta Research Lab | Nuovi derivati degli acidi 5 pentilammino 5 oxo pentaoico e 4 pentilammino 4 oxo butanoico ad attivita antagonista della colecistochinina e procedimento per la loro preparazione |
| IT1217123B (it) * | 1987-02-05 | 1990-03-14 | Rotta Research Lab | Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione |
| US4971978A (en) * | 1987-09-21 | 1990-11-20 | Nadzan Alex M | Derivatives of D-glutamic acid and D-aspartic acid |
| EP0436612A4 (en) * | 1988-09-30 | 1992-05-20 | Australian Commercial Research & Development Limited | Amino acid transport proteins, amino acid analogues, assay apparatus, uses thereof for treatment and diagnosis of cancer |
| FR2643371B1 (fr) * | 1989-02-17 | 1993-11-05 | Roussel Uclaf | Nouveaux derives de l'acide 2-amino pentanedioique, leur procede de preparation et leur application comme medicaments |
| ATE119040T1 (de) * | 1989-08-04 | 1995-03-15 | Merck Sharp & Dohme | Zentrale cholecystokinin-antagonisten zur behandlung von psychiatrischen krankheiten. |
| IE912285A1 (en) * | 1990-07-12 | 1992-01-15 | Black James Foundation | Amino acid derivatives |
| IT1241029B (it) * | 1990-12-11 | 1993-12-27 | Rotta Research Lab | Derivati amidici biciclici e policiclici degli acidi glutammico, aspartico e 2-ammino adipico ad attivita' antigastrinica e procedimento per la loro preparazione |
| US5217957A (en) * | 1991-08-20 | 1993-06-08 | Warner-Lambert Company | Cholecystokinin antagonists useful for treating depression |
| US5153191A (en) * | 1991-08-20 | 1992-10-06 | Warner-Lambert Company | Cholecystokinin antagonists useful for treating depression |
| EP0617621A4 (en) * | 1991-12-20 | 1995-04-05 | Merck Sharp & Dohme | CENTRAL CHOLECYSTOKININE ANTAGONISTS WITH PHARMACEUTICAL EFFECTIVENESS. |
| US5716958A (en) * | 1994-10-27 | 1998-02-10 | Tobishi Pharmaceutical Co., Ltd. | Amino acid derivative having anti-CCK activity |
| GB9721746D0 (en) * | 1997-10-15 | 1997-12-10 | Panos Therapeutics Limited | Compositions |
| CN1886114B (zh) * | 2003-11-27 | 2011-08-10 | 株式会社资生堂 | 角化不全抑制剂和皮肤外用组合物 |
| CN108912007B (zh) * | 2018-06-20 | 2021-02-26 | 中国农业科学院兰州畜牧与兽药研究所 | 一种右氯谷胺的制备方法 |
| CN110325052B (zh) * | 2018-11-05 | 2022-11-18 | 彭险峰 | 天门冬氨酸脂肪酰基衍生物在制备动物饲料添加剂中的应用 |
| EP3888471A4 (en) * | 2018-12-18 | 2021-12-22 | Peng, Xianfeng | USE OF A GLUTAMINE DERIVATIVE IN THE MANUFACTURE OF ANIMAL FEED ADDITIVE |
| CN113272273B (zh) * | 2019-08-15 | 2023-09-15 | 弗门尼舍有限公司 | 味道改良化合物及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2828327A (en) * | 1953-12-17 | 1958-03-25 | Monsanto Chemicals | Esters of n-aroylaspartic acids |
| US3551419A (en) * | 1964-07-31 | 1970-12-29 | Rotta Research Lab | Amino acid amides and process for their production |
| JPS5111608B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1972-06-07 | 1976-04-13 |
-
1985
- 1985-06-17 IE IE1502/85A patent/IE57892B1/en not_active IP Right Cessation
- 1985-06-17 NZ NZ212436A patent/NZ212436A/xx unknown
- 1985-06-18 US US06/746,065 patent/US4791215A/en not_active Expired - Lifetime
- 1985-06-18 CA CA000484341A patent/CA1325633C/en not_active Expired - Fee Related
- 1985-06-19 GB GB08515555A patent/GB2160869B/en not_active Expired
- 1985-06-20 FR FR8509383A patent/FR2566397B1/fr not_active Expired
- 1985-06-20 SE SE8503097A patent/SE503111C2/sv not_active IP Right Cessation
- 1985-06-20 CH CH2617/85A patent/CH674203A5/it not_active IP Right Cessation
- 1985-06-21 BE BE0/215244A patent/BE902726A/fr not_active IP Right Cessation
- 1985-06-22 ES ES544462A patent/ES8604859A1/es not_active Expired
- 1985-06-24 DE DE19853522506 patent/DE3522506A1/de active Granted
- 1985-06-24 DK DK285685A patent/DK285685A/da not_active Application Discontinuation
- 1985-06-24 AU AU44109/85A patent/AU566601B2/en not_active Ceased
- 1985-06-24 AT AT0186985A patent/AT390949B/de not_active IP Right Cessation
- 1985-06-25 NL NL8501829A patent/NL8501829A/nl not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| GB8515555D0 (en) | 1985-07-24 |
| SE503111C2 (sv) | 1996-03-25 |
| SE8503097D0 (sv) | 1985-06-20 |
| FR2566397A1 (fr) | 1985-12-27 |
| NZ212436A (en) | 1989-04-26 |
| AU566601B2 (en) | 1987-10-22 |
| AU4410985A (en) | 1986-01-02 |
| NL8501829A (nl) | 1986-01-16 |
| GB2160869A (en) | 1986-01-02 |
| DE3522506A1 (de) | 1986-01-02 |
| DE3522506C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1988-03-10 |
| BE902726A (fr) | 1985-10-16 |
| ES8604859A1 (es) | 1986-03-16 |
| FR2566397B1 (fr) | 1988-08-05 |
| GB2160869B (en) | 1988-03-16 |
| SE8503097L (sv) | 1985-12-26 |
| DK285685D0 (da) | 1985-06-24 |
| IE851502L (en) | 1985-12-22 |
| IE57892B1 (en) | 1993-05-05 |
| US4791215A (en) | 1988-12-13 |
| DK285685A (da) | 1985-12-26 |
| CA1325633C (en) | 1993-12-28 |
| ATA186985A (de) | 1990-01-15 |
| ES544462A0 (es) | 1986-03-16 |
| AT390949B (de) | 1990-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH674203A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPS62501292A (ja) | トリプトファンの医薬的活性誘導体および該誘導体を含有する医薬組成物 | |
| JP5770304B2 (ja) | 安全な化学的ミトコンドリア脱共役剤を用いたｉｉ型糖尿病及び糖尿病関連疾患の治療 | |
| RU2217144C2 (ru) | Применение эпинастина в качестве болеутоляющего средства | |
| EP3319444B1 (en) | Mu opioid receptor modulators | |
| JPH0374328A (ja) | 薬学的活性を有する中枢コレシストキニン拮抗剤 | |
| US5776972A (en) | Kappa-opiate agonists for inflammatory bowel disorders | |
| JP2005247864A (ja) | ８−アザ、６−アザ、および６，８−ジアザ−１，４−ジヒドロキノキサリン−２，３−ジオン類 | |
| JPS6154A (ja) | 抗アレルギー、抗喘息及び抗炎症剤としてのフエニルアセトアミド | |
| BR112020014584A2 (pt) | inibição do canal iônico do receptor de potencial transitório a1 | |
| KR20120101473A (ko) | 아라키돈산 유사체 및 이를 사용한 진통제 치료 방법 | |
| PT1491212E (pt) | Medicamento para distúrbios de sono | |
| JP2002536410A (ja) | 肥満の治療又は予防もしくは食欲の調節を目的とした薬学的組成物の製造におけるピロリジン誘導体の使用 | |
| Falsini et al. | Antioxidant-conjugated 1, 2, 4-triazolo [4, 3-a] pyrazin-3-one derivatives: Highly potent and selective human A2A adenosine receptor antagonists possessing protective efficacy in neuropathic pain | |
| JPH07507993A (ja) | 医薬活性を有する中枢神経系コレシストキニンアンタゴニスト | |
| BRPI0807928A2 (pt) | Métodos para identificar um ativador de lyn quinase, e para tratar diabetes em um humano, kit, e, composição | |
| RU2611623C2 (ru) | Производное 4-фенилпирролидинона-2, содержащая его композиция с ноотропной активностью, способ их получения и способ лечения или профилактики нарушений нервной системы | |
| JP7050336B2 (ja) | 重水素化化合物及びその医薬的用途 | |
| ES2445751T3 (es) | Agonistas de receptor nicotínico para el tratamiento de enfermedades inflamatorias | |
| WO2000053208A2 (en) | Small molecules having glp-2 like activity | |
| EP3409664A1 (en) | Application of substituted cinnamamide derivatives in preparation of anti-anxiety medications | |
| US20180147163A1 (en) | Combination compositions and their use in methods for treating obesity and obesity-related disorders | |
| CA2025003A1 (en) | Use of dopamine-autoreceptor agonists in the treatment of drug dependency | |
| Wang et al. | Comprehensive insights into the multifaceted roles of the transient receptor potential vanilloid 1 channel in the digestive system | |
| CA1087987A (en) | Pharmaceutical composition containing 3- phenoxypyridine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |